Peptide LibraryKLOW (GHK-Cu / KPV / BPC-157 / TB-500)
Also known as: KLOW blend, BPC-157 + TB-500 + GHK-Cu + KPV
KLOW (GHK-Cu / KPV / BPC-157 / TB-500), also called KLOW blend or BPC-157 + TB-500 + GHK-Cu + KPV, is a regenerative blend in the Multi-Mechanism Repair class. KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500, marketed for tissue repair.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- Varies
- Half-life
- Varies
- FDA status
- Not Approved
- Evidence level
- Insufficient Evidence
- Human dose established
- No
- Administration Route
- Not established in humans
- Frequency
- Not established in humans
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- Multiple (component-dependent)
Vendor price snapshot
Each vendor counts once, at the median price per mg of its own listings; the typical range is the middle half of vendors. From public vendor listings collected between Oct 2026 and Nov 2026, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 43
- Listed offers
- 67
- Median price per mg (peptide vials)
- $1.50/mg
- Typical $1.22–$1.75/mg
By form
Each form is priced on its own: a price per mg doesn't make a spray or a capsule equivalent to a vial.
- Peptide vials38 vendors · median $1.50/mg
- Sprays, route not stated2 vendors · $2.12/mg
- Capsules2 vendors · $0.686/mg
Research summary
Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studies1 reviewed source
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's KLOW (GHK-Cu / KPV / BPC-157 / TB-500) profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
KLOW (GHK-Cu / KPV / BPC-157 / TB-500) dosage: no established human dose
KLOW, a blend of GHK-Cu, KPV, BPC-157 and TB-500 in one vial, has no established human dosage. No human study has tested this blend, and none of its four components has an established human dose given by injection. GHK-Cu's human studies are topical, BPC-157 and TB-500 have only small or unfinished human studies, and KPV has no human study.
No established human dosage.
Human clinical evidence: None identified.
Preclinical research: KLOW is a vendor blend, not a studied product. Each component has its own, mostly preclinical, literature: GHK-Cu on skin and wound repair, KPV on colitis models (largely in hydrogel carriers), and BPC-157 and TB-500 on tissue repair in animals. A 2026 rat study of BPC-157 and TB-500 together found no added benefit over either alone. No study of all four together, or of GHK-Cu or KPV combined with the others, was found in PubMed or ClinicalTrials.gov.
Animal dosing is not converted into a human dose anywhere on this page. Where research figures appear below, they are reported as studied, not recommended.
| Human dosing established | No |
|---|---|
| Route | Not established in humans |
| Evidence level | Insufficient Evidence |
| Last reviewed | 2026-11-07 |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Component (analog evidence) — GHK-Cu: randomised trial on CO2 laser-resurfaced skin (Miller et al., 2006)Clinical trial · Randomised controlled trial of a topical product containing one componentStudied an analog, not KLOW (GHK-Cu / KPV / BPC-157 / TB-500) itself | Patients after circumoral CO2 laser skin resurfacing (13 completed) | Not quantified — skin care products containing the copper tripeptide complex | Topical | Per post-treatment skin care regimen | 12 weeks of follow-up | No significant difference in erythema, wrinkles or skin quality on objective or blinded evaluation; patient-rated satisfaction was higher with GHK-Cu | Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. |
| Component (analog evidence) — BPC-157: NCT07437547, phase 2, recruiting, no resultsClinical trial · Registered phase 2 placebo-controlled trial of one component aloneStudied an analog, not KLOW (GHK-Cu / KPV / BPC-157 / TB-500) itself | Adults with acute hamstring muscle strain (planned n=120) | Not disclosed in the registry record (BPC-157 alone, not a blend) | Subcutaneous | Once daily | 14 days | Hamstring muscle strain repair; no results posted | NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair |
| Component (analog evidence) — TB-500: NCT07487363, phase 1/2, recruiting, no resultsClinical trial · Registered phase 1/2 placebo-controlled trial of one component aloneStudied an analog, not KLOW (GHK-Cu / KPV / BPC-157 / TB-500) itself | Adults with stable atherosclerotic cardiovascular disease (planned n=80) | Not disclosed in the registry record (TB-500 alone, not a blend) | Not disclosed | — | — | Cardiovascular biomarkers; no results posted | NCT07487363 — TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD |
| Component (analog evidence) — KPV: hydrogel delivery in an inflamed rat colonPreclinical · Preclinical study of one component in an engineered delivery systemStudied an analog, not KLOW (GHK-Cu / KPV / BPC-157 / TB-500) itself | Rats with TNBS-induced colitis | Delivered from a double-network hydrogel into the colon; not a free-peptide dose | Intracolonic | — | — | Better relief of colitis and recovery of the colon's epithelial barrier with the hydrogel-bound KPV | A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon. Acta Biomater. 2022. |
| BPC-157 and TB-500 together — rat Achilles tendon repair (Biçer et al., 2026)Preclinical · Randomised preclinical study comparing each peptide alone and the two combined | Male Sprague-Dawley rats after Achilles tendon transection and repair (n=32, 8 per group) | BPC-157 10 µg/kg/day, TB-500 60 µg/kg/day, or both; model-specific and not convertible to a human dose | Intraperitoneal | Daily | 4 weeks | Both peptides alone improved tendon histology, and TB-500 alone improved load to failure; the combination gave no added benefit over either alone | Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026. |
Where sources disagree
- A blend's amount of any one component is not a dose that was studied for that compound. See the GHK-Cu, KPV, BPC-157 and TB-500 profiles for what each component's evidence shows.
- Shop listings sell KLOW as one total amount, most often 80 mg; where the split is given it is usually 50 mg GHK-Cu and 10 mg each of KPV, BPC-157 and TB-500, but the split is set by the seller.
- GHK-Cu's human evidence is for skin care products applied to the skin, not injection. A cream's content is not an injectable dose.
- KLOW is also sold as capsules and sprays. Nothing on this page applies to those forms.
Reconstitution
Common research vial sizes: 80 mg.
| Vial | Bacteriostatic water | Concentration | Per 0.01 mL |
|---|---|---|---|
| 80 mg | 5 mL | 16 mg/mL of total blend | 160 mcg of total blend per 0.01 mL |
These figures are arithmetic only — they convert a vial and a volume into a concentration. They are not a recommendation to take any dose.
Calculate reconstitution & dose →Handling & administration
- Reconstitution Guide
- 5 mL BAC for 80 mg blend
- Injection Sites
- Midsection
- Concentration Example
- 80 mg / 5 mL = 16 mg/mL
- Timing Notes
- Morning/post-training
- Expected Onset
- 1-2 weeks
How to reconstitute KLOW (GHK-Cu / KPV / BPC-157 / TB-500)
- Check the vial size and diluent volume. The profile example for KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is: 5 mL BAC for 80 mg blend.
- Swab both vial stoppers and draw the bacteriostatic water into a sterile syringe.
- Add the water slowly down the inside wall of the peptide vial so it does not jet onto the powder, then swirl gently until the solution is clear. Do not shake.
- Record the resulting concentration: 80 mg / 5 mL = 16 mg/mL.
- Label the vial with the date and concentration, refrigerate it (see Storage & stability below), and use the calculator preset to convert a dose in mcg into syringe units.
Open the peptide calculator with the KLOW (GHK-Cu / KPV / BPC-157 / TB-500) preset →
Sequence & molecular data
| Amino acid sequence | GHK-Cu: Gly-His-Lys-Cu; KPV: Lys-Pro-Val; BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; TB-500: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH (thymosin β4 17–23 fragment, as TB-500 is usually sold; some vendors supply full-length thymosin β4) |
|---|---|
| Molecular formula | Varies |
| Molecular weight | Varies |
| Half-life | Varies |
| Appearance | White lyophilized powder |
| Formulation | Lyophilized Powder |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500, marketed for tissue repair. The components act on separate proposed pathways: GHK-Cu on copper-dependent matrix remodelling and collagen synthesis; KPV, the C-terminal tripeptide of alpha-MSH, on NF-kB-mediated inflammatory signalling; BPC-157 on angiogenic and nitric oxide pathways in animal models; and TB-500 on actin sequestration and cell migration. As with any such blend, the combination has no mechanism beyond its parts, no pivotal trial exists for the product, and the pharmacokinetics of co-administration have not been studied. Every component is unapproved.
Origin
Commercial peptide blend.
Targets
Studies
- Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? (component evidence (ghk-cu (copper peptide)))
- Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (component evidence (ghk-cu (copper peptide)))
- A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colon (component evidence (kpv))
- Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats (component evidence (kpv))
Regulatory & research status
KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Research-Only |
How FDA approval, compounding and research-only status differ
Benefits
KLOW (GHK-Cu / KPV / BPC-157 / TB-500) side effects
KLOW (GHK-Cu / KPV / BPC-157 / TB-500) has no controlled human safety data. The effects below are reported, not established, and absence from the list is not evidence of safety.
Side Effects
- Irritation
- Nausea
Contraindications
- Copper allergy
Stacking
Common stacking partners
Combinations that include KLOW (GHK-Cu / KPV / BPC-157 / TB-500), with the proposed rationale, an evidence grade and what is not established, are catalogued in the peptide stacks directory.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
KLOW (GHK-Cu / KPV / BPC-157 / TB-500): frequently asked questions
What is KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?
Vendor regenerative blend (commonly BPC-157, TB-500, GHK-Cu, and KPV). Not a single drug; several components are WADA-prohibited or unapproved.
How does KLOW (GHK-Cu / KPV / BPC-157 / TB-500) work?
KLOW is a compounded blend of GHK-Cu, KPV, BPC-157 and TB-500, marketed for tissue repair. The components act on separate proposed pathways: GHK-Cu on copper-dependent matrix remodelling and collagen synthesis; KPV, the C-terminal tripeptide of alpha-MSH, on NF-kB-mediated inflammatory signalling; BPC-157 on angiogenic and nitric oxide pathways in animal models; and TB-500 on actin sequestration and cell migration.
Is KLOW (GHK-Cu / KPV / BPC-157 / TB-500) FDA approved?
No. KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?
Reported half-life for KLOW (GHK-Cu / KPV / BPC-157 / TB-500) is Varies. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
What is the amino acid sequence of KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?
KLOW is a blend, not a single peptide. Its components are GHK-Cu (Gly-His-Lys copper complex), KPV (Lys-Pro-Val), BPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) and TB-500, which is usually the acetylated thymosin β4 fragment Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln rather than the full 43-residue protein. There is no single molecular formula; composition depends on the vial.
What peptides are similar to KLOW (GHK-Cu / KPV / BPC-157 / TB-500)?
Compounds most often compared with KLOW (GHK-Cu / KPV / BPC-157 / TB-500) include GHK-Cu (Copper Peptide), KPV, BPC-157 and TB-500 (Thymosin Beta-4 fragment). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- WADA Prohibited List 2026External reference
- Component evidence (GHK-Cu (Copper Peptide)) — Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes?External reference
- Component evidence (GHK-Cu (Copper Peptide)) — Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene DataExternal reference
- Component evidence (KPV) — A KPV-binding double-network hydrogel restores gut mucosal barrier in an inflamed colonExternal reference
- Component evidence (KPV) — Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in RatsExternal reference
Related research, comparisons & guides
- KLOW vs GLOW: What Adding KPV Changes, and What It Does Not
- GLOW Peptide Blend: What Is Actually in the Vial
- KLOW Peptide Blend: GLOW Plus KPV, and What That Addition Changes
- The Wolverine Stack: What It Is and Where the Name Came From
- KLOW Peptide Dosage: Why No Studied Dose Exists for the Blend
- Peptide Stacks: Why Combinations Have No Evidence Base
- BPC-157 and TB-500: Why Blended Vials Break the Usual Math
- Peptide dosage chart: dose, route and frequencyCategory
- Peptide calculator with the KLOW (GHK-Cu / KPV / BPC-157 / TB-500) preset
- How to store peptides before and after reconstitution
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 4
This KLOW (GHK-Cu / KPV / BPC-157 / TB-500) profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track KLOW (GHK-Cu / KPV / BPC-157 / TB-500) research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →